Our value proposition
1. Industry outlookThe global market size of CRISPR technology was USD 1.67 Billion in 2020, expected to nearly triple by 2027. North America dominated the market with a 38% share in 2019. Biotechnology and pharmaceutical companies segment account for the largest market share of 52% in 2020.
2. Survey dataCRISPR application areas:
Primarily, CRISPR technology is used in animal models and disease models and diagnostics.
Fig-2: CRISPR application areas survey data
Fig-3: CRISPR types of editing survey data
The business model
1. Customer segmentsOdigos helps many stakeholders in the biotechnology ecosystem by streamlining time, money, and effort. A few of our target customer segments would be:
- Academic & Government Research Institutes; currently, MIT holds largest number of relevant patents
- Scientific communities
- Private Research labs
- Other CRISPR-centric companies, leveraging our software’s power through technology partnerships
2. Target application segments
Fig-4: CRISPR research areas survey data
- Reversing the mutation of cancer cells
- Cell and gene therapy
- agriculture (enhancing crops or preventing and treating animal disease)
3. Growth modelCRISPR technology is still in a nascent stage and we would like to explore & establish strategic partnerships with the below entities to grow together.
- Technology partners
- Community experts
- Contract research organizations
4. Revenue sourcesOdigos is a cloud-based software tool. Like any B2B SaaS product, we are planning to make the tool accessible through an annual/monthly subscription-based revenue model with inclusive innovation.
- Profit margins on base subscriptions & add-ons.
- Fees from companies/others that would like to use our tool’s capabilities through APIs
- Partnership sales
- Licensed use of algorithm
Table-1: Competitors list
Biotech firms - Biotech firms would have a competitive advantage by using our product by cutting their R&D expenses and timeline. For any business, cost-cutting measures are an essential part of protecting profits. Furthermore, streamlining the developmental timeline could help participating firms become more competitive in their sector of the industry.
Software Companies - Software companies could be excellent collaborators in the effort to find AI and ML solutions to genomic sequencing challenges. By licensing our technology, other software companies could continue to improve on our algorithm to pursue further advancements for lab research.
Investors - Investors have a unique opportunity by helping us patent and market our software. Investors may have the potential to profit from our venture, including from IP royalties that accrue over time.
The Chronically Ill -- Fundamentally, the most important stakeholder is the end user of the biomedical research that would be executed more quickly and cost-effectively. By cutting the timeline during important phases of research, as well as by making research a more cost-effective process, labs and private companies could make new discoveries more quickly, ultimately leading to more therapeutics available to patients more quickly. For seriously ill patients, such advances could lengthen enjoyable lifespan or increase the quality of life for people who otherwise would suffer more severely from their illnesses.
Systemic Risks - if human stem cell research is ever outlawed, that ban would present substantial hardship, although work with animal stem cells could continue
- Teece, D.J. (1986). Profiting from Technological Innovation: Implications for integration, collaboration, licensing and public policy. Research Polity, 15(6), 285- 306.